Suppr超能文献

DPPA3-HIF1α轴通过赋予缓慢的细胞周期表型来控制结直肠癌的化疗耐药性。

DPPA3-HIF1α axis controls colorectal cancer chemoresistance by imposing a slow cell-cycle phenotype.

作者信息

Cuesta-Borràs Estefania, Salvans Cándida, Arqués Oriol, Chicote Irene, Ramírez Lorena, Cabellos Laia, Martínez-Quintanilla Jordi, Mur-Espinosa Alex, García-Álvarez Alejandro, Hernando Jorge, Tejedor Juan Ramón, Mirallas Oriol, Élez Elena, Fraga Mario F, Tabernero Josep, Nuciforo Paolo, Capdevila Jaume, Palmer Héctor G, Puig Isabel

机构信息

Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain.

Stem Cells and Cancer Laboratory, Vall d'Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain; University of Barcelona, Barcelona, Spain.

出版信息

Cell Rep. 2023 Aug 29;42(8):112927. doi: 10.1016/j.celrep.2023.112927. Epub 2023 Aug 1.

Abstract

Tumor relapse is linked to rapid chemoresistance and represents a bottleneck for cancer therapy success. Engagement of a reduced proliferation state is a non-mutational mechanism exploited by cancer cells to bypass therapy-induced cell death. Through combining functional pulse-chase experiments in engineered cells and transcriptomic analyses, we identify DPPA3 as a master regulator of slow-cycling and chemoresistant phenotype in colorectal cancer (CRC). We find a vicious DPPA3-HIF1α feedback loop that downregulates FOXM1 expression via DNA methylation, thereby delaying cell-cycle progression. Moreover, downregulation of HIF1α partially restores a chemosensitive proliferative phenotype in DPPA3-overexpressing cancer cells. In cohorts of CRC patient samples, DPPA3 overexpression acts as a predictive biomarker of chemotherapeutic resistance that subsequently requires reduction in its expression to allow metastatic outgrowth. Our work demonstrates that slow-cycling cancer cells exploit a DPPA3/HIF1α axis to support tumor persistence under therapeutic stress and provides insights on the molecular regulation of disease progression.

摘要

肿瘤复发与快速产生化学抗性相关,是癌症治疗成功的一个瓶颈。进入增殖减缓状态是癌细胞利用的一种非突变机制,以绕过治疗诱导的细胞死亡。通过在工程细胞中结合功能性脉冲追踪实验和转录组分析,我们确定DPPA3是结直肠癌(CRC)中慢周期和化学抗性表型的主要调节因子。我们发现了一个恶性的DPPA3-HIF1α反馈环,该反馈环通过DNA甲基化下调FOXM1表达,从而延迟细胞周期进程。此外,HIF1α的下调部分恢复了过表达DPPA3的癌细胞中的化学敏感增殖表型。在CRC患者样本队列中,DPPA3过表达作为化疗抗性的预测生物标志物,随后需要降低其表达以允许转移灶生长。我们的研究表明,慢周期癌细胞利用DPPA3/HIF1α轴在治疗压力下支持肿瘤持续存在,并为疾病进展的分子调控提供了见解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验